Omada Health, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per-share data, unaudited)
| Three Months Ended September 30, · Nine Months Ended September 30, | ||||||
|---|---|---|---|---|---|---|
| 2025 · 2024 · 2025 · 2024 | ||||||
| Revenue | ||||||
| Services (1) | $62,936 | $42,096 | $169,392 | $112,351 | ||
| Hardware (2) | 5,094 | 3,419 | 14,972 | 9,471 | ||
| Total revenue | 68,030 | 45,515 | 184,364 | 121,822 | ||
| Cost of revenue | ||||||
| Services (3) | 12,654 | 10,631 | 38,071 | 31,686 | ||
| Hardware | 10,305 | 6,322 | 29,016 | 19,392 | ||
| Total cost of revenue | 22,959 | 16,953 | 67,087 | 51,078 | ||
| Gross profit | 45,071 | 28,562 | 117,277 | 70,744 | ||
| Operating expenses | ||||||
| Research and development (4) | 10,301 | 8,850 | 29,131 | 26,733 | ||
| Sales and marketing (5) | 22,943 | 17,577 | 65,431 | 49,964 | ||
| General and administrative (6) | 14,340 | 10,659 | 37,968 | 30,601 | ||
| Total operating expenses | 47,584 | 37,086 | 132,530 | 107,298 | ||
| Operating loss | (2,513) | (8,524) | (15,253) | (36,554) | ||
| Other income (expense), net | ||||||
| Interest expense | (353) | (1,147) | (2,521) | (3,409) | ||
| Interest income | 2,009 | 17 | 3,414 | 631 | ||
| Loss on debt extinguishment | (2,109) | - | (2,109) | - | ||
| Change in fair value of warrant liabilities | (212) | 428 | (1,468) | 445 | ||
| Total other expense, net | (665) | (702) | (2,684) | (2,333) | ||
| Loss before provision for income taxes | (3,178) | (9,226) | (17,937) | (38,887) | ||
| Provision for income taxes | - | - | - | - | ||
| Net loss and comprehensive loss | $(3,178) | $(9,226) | $(17,937) | $(38,887) | ||
| Net loss per share - basic and diluted | $(0.06) | $(1.18) | $(0.61) | $(5.09) | ||
| Weighted-average shares outstanding - basic and diluted | 57,658 | 7,788 | 29,421 | 7,644 | ||
(1)Includes amounts from a related party of $41.8 million and $23.5 million for the three months ended September 30, 2025 and 2024, respectively and $108.2 million and $62.1 million for the nine months ended September 30, 2025 and 2024, respectively.
(2)Includes amounts from a related party of $3.0 million and $1.7 million for the three months ended September 30, 2025 and 2024, respectively and $9.0 million and $4.7 million for the nine months ended September 30, 2025 and 2024, respectively.
(3)Includes amounts from a related party of $1.4 million and $0.8 million for the three months ended September 30, 2025 and 2024, respectively and $3.8 million and $2.5 million for the nine months ended September 30, 2025 and 2024, respectively.
(4)Includes amounts from a related party of $0.6 million and $0.5 million for the three months ended September 30, 2025 and 2024, respectively and $1.6 million and $1.3 million for the nine months ended September 30, 2025 and 2024, respectively.
(5)Includes amounts from a related party of $7.1 million and $3.8 million for the three months ended September 30, 2025 and 2024, respectively and $19.3 million and $11.0 million for the nine months ended September 30, 2025 and 2024, respectively.
(6)Includes amounts from a related party of $0.4 million and $0.3 million for the three months ended September 30, 2025 and 2024, respectively and $1.1 million and $0.8 million for the nine months ended September 30, 2025 and 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.